Delving into the Latest Updates on KY0135 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

KY 0135, KY-0135, KY0135

Target

Wnt

Action

inhibitors

Mechanism

Wnt inhibitors

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Jiangsu Kanion Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Kanion Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：1、评价KY0135片在晚期实体瘤患者中的安全性和耐受性。2、、确定KY0135片的最大耐受剂量(MTD)或最大爬坡剂量(MAD)，以及后续推荐剂量(RD)。次要目的：1、描述KY0135片单次、多次口服给药后的药代动力学特征。2、评价KY0135片在晚期实体瘤患者中的抗肿瘤活性。3、检测口服KY0135片后PD指标（头发毛囊的Axin2mRNA水平、血清骨转换生化指标如β-CTX）的变化。

[Translation]

Primary objectives: 1. To evaluate the safety and tolerability of KY0135 tablets in patients with advanced solid tumors. 2. To determine the maximum tolerated dose (MTD) or maximum escalation dose (MAD) of KY0135 tablets, as well as the subsequent recommended dose (RD). Secondary objectives: 1. To describe the pharmacokinetic characteristics of KY0135 tablets after single and multiple oral administration. 2. To evaluate the antitumor activity of KY0135 tablets in patients with advanced solid tumors. 3. To detect changes in PD indicators (Axin2 mRNA levels in hair follicles, serum bone turnover biochemical indicators such as β-CTX) after oral administration of KY0135 tablets.

Start Date-

Sponsor / Collaborator

Jiangsu Kanion Pharmaceutical Co., Ltd.

100 Clinical Results associated with KY0135

Login to view more data

100 Translational Medicine associated with KY0135

Login to view more data

100 Patents (Medical) associated with KY0135

Login to view more data

100 Deals associated with KY0135

Login to view more data